AU2016263598A1 - Methods and kits for treating depression - Google Patents
Methods and kits for treating depression Download PDFInfo
- Publication number
- AU2016263598A1 AU2016263598A1 AU2016263598A AU2016263598A AU2016263598A1 AU 2016263598 A1 AU2016263598 A1 AU 2016263598A1 AU 2016263598 A AU2016263598 A AU 2016263598A AU 2016263598 A AU2016263598 A AU 2016263598A AU 2016263598 A1 AU2016263598 A1 AU 2016263598A1
- Authority
- AU
- Australia
- Prior art keywords
- esketamine
- phase
- patient
- induction phase
- dosage unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 54
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims description 213
- 229960000450 esketamine Drugs 0.000 claims description 210
- 230000006698 induction Effects 0.000 claims description 109
- 238000012423 maintenance Methods 0.000 claims description 69
- 230000003442 weekly effect Effects 0.000 claims description 30
- 239000000902 placebo Substances 0.000 claims description 27
- 229940068196 placebo Drugs 0.000 claims description 27
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 80
- 239000000935 antidepressant agent Substances 0.000 description 52
- 229940005513 antidepressants Drugs 0.000 description 52
- 230000001430 anti-depressive effect Effects 0.000 description 49
- 239000007921 spray Substances 0.000 description 45
- 208000024891 symptom Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 206010042458 Suicidal ideation Diseases 0.000 description 23
- 208000024714 major depressive disease Diseases 0.000 description 23
- 208000020401 Depressive disease Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 238000004448 titration Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 7
- 206010010144 Completed suicide Diseases 0.000 description 7
- 206010054089 Depressive symptom Diseases 0.000 description 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 7
- 229960002866 duloxetine Drugs 0.000 description 7
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 7
- 229960002073 sertraline Drugs 0.000 description 7
- 229960004341 escitalopram Drugs 0.000 description 6
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229960003299 ketamine Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 239000007894 caplet Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 206010042464 Suicide attempt Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000024732 dysthymic disease Diseases 0.000 description 4
- 201000003104 endogenous depression Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010049119 Emotional distress Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010065604 Suicidal behaviour Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000009429 distress Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- -1 nefazadone Chemical compound 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 206010020765 hypersomnia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 230000009430 psychological distress Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- YQEZLKZALYSWHR-CYBMUJFWSA-N (R)-(+)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@]1(NC)CCCCC1=O YQEZLKZALYSWHR-CYBMUJFWSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- 206010050013 Abulia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010013470 Dissociative states Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010057371 Hypoaesthesia oral Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- VCMGMSHEPQENPE-ZOWNYOTGSA-N esketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1[C@@]1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-ZOWNYOTGSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960005197 quetiapine fumarate Drugs 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021215155A AU2021215155A1 (en) | 2015-05-20 | 2021-08-11 | Methods and kits for treating depression |
| AU2023237026A AU2023237026A1 (en) | 2015-05-20 | 2023-09-25 | Methods and kits for treating depression |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164026P | 2015-05-20 | 2015-05-20 | |
| US62/164,026 | 2015-05-20 | ||
| PCT/US2016/033404 WO2016187491A1 (en) | 2015-05-20 | 2016-05-20 | Methods and kits for treating depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021215155A Division AU2021215155A1 (en) | 2015-05-20 | 2021-08-11 | Methods and kits for treating depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016263598A1 true AU2016263598A1 (en) | 2017-11-23 |
| AU2016263598A8 AU2016263598A8 (en) | 2017-11-30 |
Family
ID=57320901
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016263598A Abandoned AU2016263598A1 (en) | 2015-05-20 | 2016-05-20 | Methods and kits for treating depression |
| AU2021215155A Abandoned AU2021215155A1 (en) | 2015-05-20 | 2021-08-11 | Methods and kits for treating depression |
| AU2023237026A Abandoned AU2023237026A1 (en) | 2015-05-20 | 2023-09-25 | Methods and kits for treating depression |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021215155A Abandoned AU2021215155A1 (en) | 2015-05-20 | 2021-08-11 | Methods and kits for treating depression |
| AU2023237026A Abandoned AU2023237026A1 (en) | 2015-05-20 | 2023-09-25 | Methods and kits for treating depression |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160338977A1 (https=) |
| EP (1) | EP3297618A4 (https=) |
| JP (1) | JP2018515557A (https=) |
| KR (1) | KR20180008634A (https=) |
| CN (1) | CN107735081A (https=) |
| AU (3) | AU2016263598A1 (https=) |
| CA (1) | CA2986477A1 (https=) |
| CL (1) | CL2017002904A1 (https=) |
| CO (1) | CO2017011564A2 (https=) |
| DO (1) | DOP2017000268A (https=) |
| EA (1) | EA201792545A1 (https=) |
| EC (1) | ECSP17077930A (https=) |
| GT (1) | GT201700246A (https=) |
| HK (1) | HK1252937A1 (https=) |
| IL (1) | IL255463A (https=) |
| MA (1) | MA42135A (https=) |
| MX (1) | MX2017014797A (https=) |
| PE (1) | PE20180260A1 (https=) |
| PH (1) | PH12017502103A1 (https=) |
| WO (1) | WO2016187491A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| KR20170040800A (ko) | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| KR20240011237A (ko) * | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| BR112020023882A2 (pt) * | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020070547A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2022524008A (ja) * | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| CN114286674A (zh) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮 |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| JP7840873B2 (ja) * | 2020-05-28 | 2026-04-06 | ヤンセン ファーマシューティカ エヌ．ベー． | うつ病の治療方法 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| DK2983787T3 (da) * | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
-
2016
- 2016-05-19 US US15/159,257 patent/US20160338977A1/en not_active Abandoned
- 2016-05-20 EA EA201792545A patent/EA201792545A1/ru unknown
- 2016-05-20 HK HK18112292.0A patent/HK1252937A1/zh unknown
- 2016-05-20 AU AU2016263598A patent/AU2016263598A1/en not_active Abandoned
- 2016-05-20 CA CA2986477A patent/CA2986477A1/en not_active Abandoned
- 2016-05-20 JP JP2017560314A patent/JP2018515557A/ja active Pending
- 2016-05-20 KR KR1020177036002A patent/KR20180008634A/ko not_active Withdrawn
- 2016-05-20 PE PE2017002425A patent/PE20180260A1/es unknown
- 2016-05-20 CN CN201680029082.XA patent/CN107735081A/zh active Pending
- 2016-05-20 WO PCT/US2016/033404 patent/WO2016187491A1/en not_active Ceased
- 2016-05-20 MX MX2017014797A patent/MX2017014797A/es unknown
- 2016-05-20 MA MA042135A patent/MA42135A/fr unknown
- 2016-05-20 EP EP16797348.6A patent/EP3297618A4/en not_active Withdrawn
-
2017
- 2017-11-06 IL IL255463A patent/IL255463A/en unknown
- 2017-11-14 CO CONC2017/0011564A patent/CO2017011564A2/es unknown
- 2017-11-15 CL CL2017002904A patent/CL2017002904A1/es unknown
- 2017-11-16 GT GT201700246A patent/GT201700246A/es unknown
- 2017-11-17 DO DO2017000268A patent/DOP2017000268A/es unknown
- 2017-11-20 PH PH12017502103A patent/PH12017502103A1/en unknown
- 2017-11-23 EC ECIEPI201777930A patent/ECSP17077930A/es unknown
-
2021
- 2021-08-11 AU AU2021215155A patent/AU2021215155A1/en not_active Abandoned
-
2023
- 2023-09-25 AU AU2023237026A patent/AU2023237026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GT201700246A (es) | 2019-07-29 |
| CL2017002904A1 (es) | 2018-04-20 |
| IL255463A (en) | 2018-01-31 |
| KR20180008634A (ko) | 2018-01-24 |
| JP2018515557A (ja) | 2018-06-14 |
| EA201792545A1 (ru) | 2018-05-31 |
| ECSP17077930A (es) | 2018-02-28 |
| PE20180260A1 (es) | 2018-02-05 |
| CO2017011564A2 (es) | 2018-04-19 |
| DOP2017000268A (es) | 2018-04-15 |
| US20160338977A1 (en) | 2016-11-24 |
| HK1252937A1 (zh) | 2019-06-06 |
| EP3297618A1 (en) | 2018-03-28 |
| PH12017502103A1 (en) | 2018-05-07 |
| AU2021215155A1 (en) | 2021-09-02 |
| CA2986477A1 (en) | 2016-11-24 |
| AU2016263598A8 (en) | 2017-11-30 |
| AU2023237026A1 (en) | 2023-10-12 |
| EP3297618A4 (en) | 2019-01-23 |
| WO2016187491A1 (en) | 2016-11-24 |
| MA42135A (fr) | 2018-03-28 |
| CN107735081A (zh) | 2018-02-23 |
| MX2017014797A (es) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023237026A1 (en) | Methods and kits for treating depression | |
| US20250255835A1 (en) | Methods For The Treatment Of Depression | |
| CA3086478A1 (en) | Esketamine for the treatment of depression | |
| CN104519878A (zh) | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 | |
| US20240325296A1 (en) | Esketamine for the treatment of depression | |
| AU2014281414A1 (en) | Use of high dose pridopidine for treating Huntington's disease | |
| Ventura et al. | Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial | |
| US20200009081A1 (en) | Delivery Of Esketamine For The Treatment Of Depression | |
| CA3153856A1 (en) | Intranasal administration of esketamine | |
| Farmer et al. | Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full | |
| Amsterdam et al. | Once-versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study | |
| Sanacora | Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants. | |
| EP4687860A1 (en) | Esketamine for use in the treatment of depression | |
| AU2013201492A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| AU2013203567A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| Trinza | DA US FDA Approved for | |
| TW201002719A (en) | Treatment of attention-deficit/hyperactivity disorder | |
| Lubetsky | Benjamin L. Handen, Tiberiu Bodea, Rameshwari V. Tumuluru, and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 31 , NO 46 , PAGE(S) 6665 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME JANSSEN PHARMACEUTICA NV, APPLICATION NO. 2016263598, UNDER INID (72) REMOVE CO-INVENTOR SHIRTZ, JOSEPH; UNDER INID (72) ADD CO-INVENTOR SINGH, JASKARAN |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |